With $7.5 billion in funding over 5 years, Gavi aims to: 1) Increase the proportion of fully immunized children in Gavi-supported countries from 5% to 50% 2) Save 5-6 million lives and avert over 100 million cases of illness 3) Generate $80-100 billion in economic benefits from reduced treatment costs and increased productivity

1. Gavi 2016–2020
What the Vaccine Alliance
can achieve together in
the next five-year period
1 #vaccineswork
Gavi/2011/DounePorter

2. THE ASK FOR 2016–2020
2 #vaccineswork
US$ 7.5
billion
additional funding
needed for immunisation
programmes through to 2020
Gavi/2013/AssadZaidi
(US$ billion)

3. ACCELERATING IMPACT 2016–2020
With US$ 7.5 billion over 5 years:
3
Fully protected
children increase
from 5%
to 50%
Economic
benefits total
US$ 80–
100 billion
#vaccineswork

4. GAVI, THE VACCINE ALLIANCE, 2016–2020
Protect past investments and pave the way to sustainability
4
all countries
co-
financing
22
graduated
countries
strengthening
health
systems
transforming
vaccine
markets
#vaccineswork
US$ 7.5
billion over
5 years
will help to achieve
all this

5. CLOSING THE IMMUNISATION GAP
Vaccine coverage in Gavi-supported countries by 2020
5
a 2012 coverage estimates are based on country official reported figures.
b Target population and coverage estimates are based on 32 yellow fever-endemic Gavi-supported countries in
Africa.
c Target population for HPV3 is 9-13 year old girls, 2012 coverage estimates derived from SDF projections
about scale-up.
Sources: 2012: WHO/UNICEF coverage estimates and country official reported figures (MCV2 and rubella),
as of July 2013. 2015 and 2020 coverage: Gavi Strategic Demand Forecast version 9.
#vaccineswork

6. 50% OF CHILDREN IN GAVI-SUPPORTED
COUNTRIES FULLY IMMUNISED BY 2020
Immunisation coverage in Gavi-supported countries (%)
6
Source: Preliminary Gavi projections based on WHO/UNICEF coverage estimates and Strategic Demand
Forecast version 9.
Fully immunised
children (73 Gavi-
supported countries)
#vaccineswork

7. BEYOND CO-FINANCING NEW VACCINES
Increasing domestic expenditure on immunisation
7
Source: Preliminary findings from Johns Hopkins and GVAP Steering Committee (2014), Costing, Financing,
Gap, and Return on Investment Analysis for Global Vaccine Action Plan (GVAP).
2011-2015
US$ 8 billion
2016-2020
US$ 12 billion
2011-2015
US$ 0.47
billion
2016-2020
US$ 1.2 billion
Gavi co-financing
Total domestic investments
in immunisation
+250%
+50%
#vaccineswork

8. ECONOMIC BENEFITS OF IMMUNISATION
in Gavi-supported countries, 2016–2020
8
5–6
million
lives saved
+100
million
illness cases averted
80–100
US$ billion
costs averted
related to illness:
• productivity loss due
to death/disability
• treatment costs
• caretaker productivity loss
• transport costs
Sources: Update using methods from 1) Lee LA et al. The estimated mortality impact of vaccinations forecast
to be administered during 2011–2020 in 73 countries supported by Gavi. Vaccine 2013; 2) Stack M et al.
Estimated economic benefits during Decade of Vaccines, Health Affairs 2011.
#vaccineswork
Gavi/2012/SalaLewis

9. EFFICIENCY
9 #vaccineswork
97% of Gavi expenditure directly supports programmes,
2016–2020
(US$ billion)

10. WHAT WE WILL ACHIEVE TOGETHER
10 #vaccineswork
additional children immunised of total number of children
immunised in the world
=
2016–2020

11. WHAT WE WILL ACHIEVE TOGETHER
11 #vaccineswork
Prevent more
future deaths
than children
born in the EU
every year
2016–2020
Gavi/2013/EvelynHockstein